Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Arthritis & Rheumatology (Hoboken, N.J.)|August 4, 2018
Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled StudyKenneth G Saag, Michael A Becker, Andrew Whelton, et al.
Nature|November 9, 2018
Superfluorescence from lead halide perovskite quantum dot superlatticesGabriele Rainò, Michael A Becker, Maryna I Bodnarchuk, et al.
Seminars in Arthritis and Rheumatism|July 21, 2015
An open-label, 6-month study of allopurinol safety in gout: The LASSO studyMichael A Becker, David Fitz-Patrick, Hyon K Choi, et al.
The Journal of Rheumatology|December 7, 2005
Tophaceous gout: quantitative evaluation by direct physical measurementH Ralph Schumacher, Michael A Becker, William A Palo, et al.
Arthritis Research & Therapy|March 5, 2014
Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic goutPeter E Lipsky, Leonard H Calabrese, Arthur Kavanaugh, et al.
Arthritis Research & Therapy|April 8, 2010
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trialMichael A Becker, H Ralph Schumacher, Luis R Espinoza, et al.
Nano Letters|June 27, 2020
Trion Emission Dominates the Low-Temperature Photoluminescence of CdSe NanoplateletsFelipe V Antolinez, Freddy T Rabouw, Aurelio A Rossinelli, et al.
ACS Nano|November 11, 2020
Unraveling the Origin of the Long Fluorescence Decay Component of Cesium Lead Halide Perovskite NanocrystalsMichael A Becker, Caterina Bernasconi, Maryna I Bodnarchuk, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 27, 2016
Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study)Kenneth G Saag, David Fitz-Patrick, Jeff Kopicko, et al.
Arthritis and Rheumatism|November 1, 2008
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trialH Ralph Schumacher, Michael A Becker, Robert L Wortmann, et al.
Pageof 6